BioCentury
ARTICLE | Company News

Biogen adds to stroke portfolio with Cirara acquisition

May 15, 2017 10:11 PM UTC

Biogen Inc. (NASDAQ:BIIB) acquired acute ischemic stroke candidate Cirara glyburide (RP-1127) from Remedy Pharmaceuticals Inc. (New York, N.Y.). Remedy is to receive $120 million up front and is eligible for milestones and royalties.

Biogen spokesperson Matt Fearer told BioCentury that Biogen will fund the majority of Cirara's development costs and all of its commercialization costs, but the companies said Remedy will "share in the cost" of the candidate's development in its target indication, large hemispheric infarction (LHI), a severe form of ischemic stroke that leads to cerebral edema...